



Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 28 June 2021

Noxopharm Corporate Presentation

Sydney 28 June 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide the attached Corporate Presentation ahead of investor presentations this week.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm also has drug discovery programs running in both oncology and inflammation, and is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR) which is active in the areas of cardiovascular and neurological disorders.

To learn more, please visit: noxopharm.com

END

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Investor, Corporate & Media enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”,

“continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



Delivering Science.
Transforming Lives

NOXOPHARM CORPORATE PRESENTATION

JUNE 2021

Dr Graham Kelly
CEO and Managing Director
NOXOPHARM LIMITED (ASX:NOX)



Discover



Develop



Deliver



DISCLAIMER



This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

WHAT DISTINGUISHES NOXOPHARM (ASX:NOX)



A technology platform offering multiple opportunities – *not isolated high-risk drug opportunities*



A platform offering a revolutionary concept in therapeutics



A platform offering outcomes highly sought in the industry



A platform we own outright – *no licence fees/ milestones/royalties etc*



The opportunities involve 2 therapeutic fields (cancer, septic shock) responsible for 40% of all deaths from disease (~20 million) p.a.



Over 5 separate indications and growing



Cancer: ability to turn 'COLD' tumours to 'HOT' – a highly sought effect in the pharma industry



Run by management team highly experienced in drug development and product commercialisation

FOUR R&D BUSINESSES IN ONE COMPANY



Veyonda®

Cancer treatment enhancement



Cancer Research Pipeline

Cancer growth factor inhibitors



Veyonda®


Septic shock



pharmorage

Chronic inflammatory diseases/autoimmune diseases

1. VEYONDA® - CANCER TREATMENT ENHANCEMENT



A revolutionary concept in cancer therapy involving a drug (Veyonda®) with multiple mechanisms of action that boosts the effectiveness of other standard anti-cancer therapies

Programs



IONIC - checkpoint inhibitor therapy



DARRT - radiotherapy



CEP - chemotherapy



LuPIN - radioligand therapy

2. CANCER RESEARCH PIPELINE - CANCER GROWTH FACTOR INHIBITORS



Many cancers, particularly the highly aggressive cancers, co-opt supporting healthy cells to supply growth factors that drive cancer cell growth.

NOX has identified a novel family of drugs with potential to block these signals

Programs



Brain cancer (GBM)




Pancreatic cancer

3. VEYONDA® - SEPTIC SHOCK



Cytokine release syndrome (CRS) is an inappropriately excessive immune response to viral and bacterial infections

Abnormal activation of STING signalling (response to tissue damage) thought to have key involvement in CRS




Veyonda believed to be first inhibitor of STING to reach the clinic

4. PHARMORAGE - CHRONIC INFLAMMATORY DISEASES/ AUTOIMMUNE DISEASES



pharmorage

Pharmorage, a collaboration between NOX and Hudson Institute of Medical Research, has identified a new family of drug compounds with highly selective activity against STING



Inappropriate STING signalling also now accepted as key cause of chronic inflammatory diseases (eg. rheumatoid arthritis) and autoimmune diseases (eg. motor neurone disease)

STING antagonists now centre of major industry interest as new drug class

OUR MANAGEMENT



Dr Graham Kelly BSc(Vet), BVSc, PhD
Chief Executive Officer

Extensive experience in the biotechnology sector. Founder of four public companies: Noxopharm (ASX:NOX), Novogen (now Kazia) ASX- KZA), MEI Pharma (NASDAQ – MEIP) Nyrada, Inc (ASX:NYR)



Dr Gisela Mautner MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg)
Chief Medical Officer

Medical scientific leader in oncology and other therapeutic areas with wide-ranging experience in senior roles in the pharmaceutical industry.



Jeanette Bell BMedSc, MScM
Chief Operating Officer

Senior leadership roles in pharmaceutical industry: working across clinical research, R&D portfolio management, global operations, sales, marketing, and launch excellence leader



Shawn van Boheemen BBus, MCom, FCPA, JP
Chief Financial Officer

Senior finance executive having held finance leadership roles across manufacturing, service based and financial services industries



Dr Olivier Laczka PhD
Group Chief Scientific Officer


Extensive industry and academic research experience in molecular and cell biology, biotechnology and drug development



Dr John Wilkinson PhD, BSc
Chief Technical Officer

Established life scientist with a strong track record in oncology, virology, drug development and clinical research in the settings of academia, biotech and big pharma

KEY METRICS (at 23 June 2021)




News Flow (next 6 months)

- IONIC-1, DARRT-2 & CEP-2 start patient recruitment
- COVID-19 clinical trial completion
- Novel drug pipeline progress
- Pharmorage progressing novel drug development for chronic inflammation and autoimmunity

OUR VALUE PROPOSITION



What drug development companies rarely tell you



Only ~ 4% of anti-cancer drugs that enter human trials make it to market

We are significantly de-risked

Multiple shots on goal

Not limited to a single therapeutic field

Aim is to assist existing therapies, not rely on the test drug carrying the full load

Areas of major medical need and industry interest



FOR FURTHER INFORMATION:



info@noxopharm.com



www.noxopharm.com



[@Noxopharm](https://twitter.com/Noxopharm)



Discover



Develop



Deliver

